Skip to content

Press Release · Press Releases

New clinical data on lecanemab to be presented at CTAD conference 2026

Issued by PR Newswire

STOCKHOLM, October 30, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present new clinical and real-world evidence on lecanemab (Leqembi®) at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, November 16-19, 2026. The...

This press release summary is reproduced from the issuer's public feed.

Read the full release at PR Newswire

Original publisher: PR Newswire

Spotted an error? Request a correction · Corrections Policy

Related stories